<DOC>
	<DOC>NCT02965417</DOC>
	<brief_summary>This is a single arm, phase 2, open-label, multicenter trial in patients with metastatic colorectal cancer (mCRC) and acquired resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) and documented mutation of extra cellular domain EGFR (ECD-EGFR).</brief_summary>
	<brief_title>Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Inclusion and Exclusion criteria have been removed due to Symphogen's business decision to no longer perform the clinical study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Resistance to anti-EGFR monoclonal antibodies</keyword>
	<keyword>Mutation of ECD-EGFR</keyword>
</DOC>